

The information in the press release is intended for investors.

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2022

GOTHENBURG, Sweden, April 6, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company's annual report and corporate governance report for the financial year 2022 are now available, in Swedish, on the company's website, www.isofolmedical.com.

For further information, please contact

Isofol Medical AB (publ)

Thomas Andersson, Chief Executive Officer

E-mail: thomas.andersson@isofolmedical.com

Phone: +46 (0) 709 44 00 93

Roy Jonebrant, Chief Financial Officer

E-mail: roy.jonebrant@isofolmedical.com

Phone: +46 (0) 708 48 12 36

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 09:00 CEST on April 6, 2023.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com